Medtronic v. Speyside Medical: Federal Circuit Appeal Voluntarily Dismissed
Medtronic and Speyside Medical jointly agreed to dismiss a Federal Circuit invalidity appeal over US9445897B2, a patent covering a prosthetic implant delivery device with introducer catheter. The parties struck a deal within 687 days of filing, with each side bearing its own costs — leaving the merits of the patent’s validity unresolved on appeal.
A medtech invalidity appeal ended by agreement, not adjudication
Medtronic, Inc. filed this Federal Circuit appeal on 19 October 2022 in connection with Case No. 23-1053, challenging an invalidity or cancellation action brought by Speyside Medical, LLC against US9445897B2 — a patent protecting a prosthetic implant delivery device with introducer catheter, filed under application number US13/777745. The dispute landed at the Court of Appeals for the Federal Circuit, the exclusive appellate venue for U.S. patent validity matters.
The appeal closed on 5 September 2024 via a joint agreement to dismiss under Federal Rule of Appellate Procedure 42(b). The court’s order reflects a mutual consent arrangement: both parties agreed to walk away, with each side bearing its own litigation costs. Crucially, the Federal Circuit issued no ruling on the merits of patentability, meaning the validity of US9445897B2 was neither confirmed nor negated by this proceeding.
A 687-day appeal lifecycle that ends in voluntary dismissal typically suggests the parties reached a commercial or licensing resolution outside the courtroom, though the public record is silent on any underlying agreement. The absence of a cost-shifting order — which courts sometimes use to signal misconduct or bad faith — is consistent with a negotiated exit. What drove Speyside Medical and Medtronic to settle at the appellate stage, and on what terms, remains undisclosed.
Filing to Voluntary dismissal in 687 days
687 days from filing to closure — slightly below the Federal Circuit’s average appeal cycle
Appeal voluntarily dismissed: what the Rule 42(b) exit means for both parties
Fed. R. App. P. 42(b): a consensual appellate exit
Rule 42(b) allows parties to jointly dismiss a Federal Circuit appeal by stipulation. It is a procedural off-ramp — not a merits ruling. The court does not evaluate validity, claim construction, or prior art. The result is that the record below stands as last decided, but no appellate precedent is created and no new legal standard is established by this dismissal.
No merits adjudicationValidity of US9445897B2 remains unresolved by this appeal
Because the Federal Circuit dismissed on consent rather than ruling on patentability, the public record does not confirm whether US9445897B2 is valid or invalid. The dismissal is silent on whether it is with or without prejudice to any underlying PTAB or district court proceeding. Practitioners should check the procedural posture of any parallel proceedings before drawing conclusions about the patent’s enforceability.
Validity question openSpeyside Medical exits without a cancellation ruling in its favour
Speyside Medical, having pursued an invalidity or cancellation action, agreed to dismiss the appeal before the Federal Circuit resolved the underlying challenge. This means Speyside did not obtain a final appellate order cancelling or invalidating the patent claims it contested. Whether the challenger secured commercial concessions in a side agreement is unknown from the public record.
No cancellation orderAgreed exit at appellate stage suggests commercial resolution
In medtech patent disputes, a mutual Rule 42(b) dismissal at the Federal Circuit — especially after nearly two years of proceedings — is consistent with a licensing arrangement, cross-licensing deal, or broader commercial settlement. Competitors and R&D teams in the prosthetic implant delivery space should note that the patent remains on the register and its enforcement posture is unchanged by this dismissal.
Likely licensing resolutionFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Medtronic, Inc. | Company | Medical device manufacturer — holder of US9445897B2, prosthetic implant deliverySearch in Eureka ↗ |
| Defendant | Speyside Medical, LLC | Company | Speyside Medical, LLC — medical device challenger pursuing patent invalidity/cancellationSearch in Eureka ↗ |
| Plaintiff counsel | Douglas HallwardDriemeier | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James Lawrence Davis | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Ropes & Gray, LLP | Law Firm | Representing Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Brian P. Biddinger | Attorney | Counsel for Speyside Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | Brian P. Egan | Attorney | Counsel for Speyside Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | Derek L. Shaffer | Attorney | Counsel for Speyside Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | James Baker | Attorney | Counsel for Speyside Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | Jared Weston Newton | Attorney | Counsel for Speyside Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | Nima Hefazi | Attorney | Counsel for Speyside Medical, LLCSearch in Eureka ↗ |
| Defendant counsel | Steven Cherny | Attorney | Counsel for Speyside Medical, LLCSearch in Eureka ↗ |
| Defendant law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Speyside Medical, LLCSearch in Eureka ↗ |
| Defendant law firm | Quinn Emanuel Urquhart & Sullivan, LLP | Law Firm | Representing Speyside Medical, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The court’s order records a joint stipulation of dismissal under Fed. R. App. P. 42(b), with each side bearing its own costs. This phrasing confirms the dismissal was mutual — neither party was compelled to exit — and that the court imposed no fee sanction or cost award. Critically, no appellate merits ruling was issued: the Federal Circuit made no finding on patentability, claim validity, or the underlying invalidity action. The cost-neutrality clause, standard in consent dismissals, does not indicate relative litigation strength or concession by either side.
US9445897B2 — Prosthetic Implant Delivery Device with Introducer Catheter
US9445897B2, filed under application number US13/777745, protects a prosthetic implant delivery device incorporating an introducer catheter — a technically complex medical device system used to deliver prosthetic implants, likely in cardiovascular or structural heart applications given Medtronic’s core portfolio. The ‘B2’ designation indicates the patent was examined and granted with a B2 publication, reflecting a prior publication before grant. The patent sits within the high-value segment of interventional medtech, where delivery system innovations carry significant commercial and clinical weight.
For Medtronic, a granted patent on an implant delivery mechanism with catheter integration represents a meaningful barrier to entry in a market where delivery precision directly affects clinical outcomes and product differentiation. Speyside Medical’s invalidity challenge — pursued through what appears to be a PTAB or similar cancellation route before reaching the Federal Circuit — signals that competitors view the patent’s claims as potentially vulnerable to prior art. The voluntary dismissal without a merits ruling preserves the patent’s registered status, but the underlying challenge suggests the claim scope is contested and commercially significant.
Should you run an FTO search against US9445897B2?
Any company developing, manufacturing, or commercialising prosthetic implant delivery devices that incorporate introducer catheter technology should assess freedom-to-operate against US9445897B2. The patent’s survival of a Federal Circuit appeal — even by voluntary dismissal — means it remains an active enforcement risk. Medical device startups, catheter manufacturers, and structural heart technology teams are the most directly exposed.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the claim language of US9445897B2, surface relevant prior art that may affect validity, and identify related Medtronic family members that could extend the patent’s coverage. Given the unresolved validity question from this appeal, an FTO analysis combining claim mapping and prior art landscaping is particularly valuable before any commercialisation decision.
Run a freedom-to-operate analysis on US9445897B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in prosthetic implant & medtech patent validity
Federal Circuit cases involving medtech implant delivery patent invalidity challenges — including IPR appeals and Rule 42(b) dismissals in the cardiovascular and structural heart device space.
What this case signals for the medtech implant delivery IP landscape
A Federal Circuit appeal dropped by mutual consent raises questions about patent risk, licensing strategy, and FTO exposure in prosthetic implant delivery.
US9445897B2 survives this challenge without a validity ruling
The voluntary dismissal means Medtronic’s implant delivery patent was never invalidated by the Federal Circuit. Competitors operating in the prosthetic implant delivery space should treat the patent as still enforceable and conduct FTO analysis before commercialising overlapping technology.
Cost neutrality signals a negotiated commercial resolution
The order’s equal cost-bearing provision is consistent with a mutual compromise rather than a unilateral capitulation. This pattern — two years of litigation ending with symmetric cost allocation — typically signals a licensing or settlement structure that both parties found commercially preferable to an appellate ruling on validity.
Medtronic v Speyside — key questions answered
The Federal Circuit appeal was voluntarily dismissed by joint agreement under Fed. R. App. P. 42(b) on 5 September 2024, with each side bearing its own costs. No merits ruling on the validity of US9445897B2 was issued. The case concerned an invalidity or cancellation action against Medtronic’s prosthetic implant delivery device patent.
The Federal Circuit issued no ruling on the validity of US9445897B2. The patent remains on the register and was not invalidated by this proceeding. However, the dismissal is silent on whether any parallel PTAB or district court validity challenges remain active. Practitioners should check for related proceedings before drawing conclusions about long-term enforceability.
Federal Rule of Appellate Procedure 42(b) permits parties to jointly stipulate to dismissal of an appeal. It is a procedural mechanism, not a merits adjudication. The court makes no ruling on patentability, claim scope, or prior art. The record as last decided below stands, but no appellate precedent is established and no new legal standard is created.
The public record does not disclose the reasons. A mutual Rule 42(b) dismissal after nearly two years of proceedings is consistent with a licensing arrangement, commercial settlement, or cross-licensing agreement reached outside the courtroom. The equal cost-bearing provision suggests a negotiated exit rather than a unilateral concession, but the underlying terms remain undisclosed.
US9445897B2, filed as US13/777745, covers a prosthetic implant delivery device incorporating an introducer catheter. This class of technology is central to minimally invasive implant procedures, including structural heart interventions. Delivery system patents in medtech carry significant commercial value because precision and ease of implant delivery are key clinical differentiators and barriers to competitive product entry.
PatSnap Eureka searches patents and litigation data to answer instantly.